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tuses and reflects a spectrum of possible uropathies. There is significant variability in the clin-
ical management of individuals with prenatal UT dilation that stems from a paucity of
evidence-based information correlating the severity of prenatal UT dilation to postnatal uro-
logical pathologies. The lack of correlation between prenatal and postnatal US findings and
final urologic diagnosis has been problematic, in large measure because of a lack of consensus
and uniformity in defining and classifying UT dilation. Consequently, there is a need for a uni-
fied classification system with an accepted standard terminology for the diagnosis and manage-
ment of prenatal and postnatal UT dilation.oi.org/10.1016/j.jpurol.2014.10.001.
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Multidisciplinary consensus on the classification of prenatal and postnatal dilation 983Methods: A consensus meeting was convened on March 14e15, 2014, in Linthicum, Maryland,
USA to propose: 1) a unified description of UT dilation that could be applied both prenatally
and postnatally; and 2) a standardized scheme for the perinatal evaluation of these patients
based on sonographic criteria (i.e. the classification system). The participating societies
included American College of Radiology, the American Institute of Ultrasound in Medicine,
the American Society of Pediatric Nephrology, the Society for Fetal Urology, the Society for
Maternal-Fetal Medicine, the Society for Pediatric Urology, the Society for Pediatric Radiology
and the Society of Radiologists in Ultrasounds.
Results: The recommendations proposed in this consensus statement are based on a detailed
analysis of the current literature and expert opinion representing common clinical practice.
The proposed UTD Classification System (and hence the severity of the UT dilation) is based
on six categories in US findings: 1) anterior-posterior renal pelvic diameter (APRPD); 2) calyceal
dilation; 3) renal parenchymal thickness; 4) renal parenchymal appearance; 5) bladder abnor-
malities; and 6) ureteral abnormalities. The classification system is stratified based on gesta-
tional age and whether the UT dilation is detected prenatally or postnatally. The panel also
proposed a follow-up scheme based on the UTD classification.
Conclusion: The proposed grading classification system will require extensive evaluation to
assess its utility in predicting clinical outcomes. Currently, the grading system is correlated
with the risk of postnatal uropathies. Future research will help to further refine the classifica-
tion system to one that correlates with other clinical outcomes such as the need for surgical
intervention or renal function.
ª 2014 Published by Elsevier Ltd on behalf of Journal of Pediatric Urology Company. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).Introduction
Prenatal diagnosis of urinary tract (UT) dilation occurs in
1e2% of all pregnancies. Based on an estimated birth rate
in the United States of 4 million per year [1], approximately
40e80,000 children are diagnosed annually with this con-
dition. The prenatal sonographic identification of UT dila-
tion reflects a spectrum of potential etiologies and
uropathies. The rationale of prenatal detection is to iden-
tify pathology prior to the development of complications
such as urinary tract infection (UTI), urinary stone forma-
tion, and renal dysfunction. In the majority of the cases,
the prenatal finding of UT dilation is transient or physiologic
and has no clinical significance. In other cases, it represents
obstructive conditions such as posterior urethral valves
(PUV) that have significant morbidities and even mortalities
(Table 1). In many of the cases, the etiology of UT dilation
is unable to be determined before birth and is diagnosed
postnatally with additional imaging including ultrasound
(US) and voiding cystourethrogram (VCUG).
Clinical practice patterns vary considerably regarding
recommendation for the follow-up evaluation of fetuses
and children who have been diagnosed with prenatal UT
dilation. This stems from the challenge of predicting which
children will have a clinically significant uropathy and
would benefit from postnatal imaging. Evaluating every
child with prenatal UT dilation results in the expenditure of
significant healthcare resources and could cost over $90
million annually (1e3 prenatal US scans at $500; antibiotics
at $25; 1e3 postnatal US scans at $400; 1 VCUG at $1200 per
child). This does not factor in the cost associated with
travel, time off from work for the parents, unnecessary
parental anxiety, childhood radiation, and antibioticexposure. Alternatively, not evaluating any child with pre-
natal UT dilation could avoid these initial costs but might
delay the diagnosis of significant uropathies such as PUV
and consequently, incur higher long-term health and
financial costs.
Evidence correlating the severity of prenatal UT dila-
tion with postnatal urological pathologies is lacking for
several reasons. First, there is no uniformity on how to
define, classify, and grade UT dilation both within and
between the prenatal and postnatal periods. As a result,
several different classification systems have evolved,
leading to varying nomenclature. Second, different ter-
minologies with overlapping meanings are used to describe
UT dilation, and different clinicians may use the terms to
mean different things. This causes misunderstanding,
which further leads to confusion as to the specific US
findings identified. For example, the term hydronephrosis
is often used by imagers to describe even mild degrees of
UT dilation, while clinicians (especially among primary
care providers) consider the term hydronephrosis to mean
distension of the renal pelvis and calyces from obstruction
of urine flow that, if left untreated, results in progressive
renal deterioration. Thus, the communication of the
findings, which is transmitted between the imager and the
clinician, may be misinterpreted. Third, UT dilation is a
dynamic process, which can fluctuate over time and with
varying conditions. The distension of the renal pelvis and
calyces may vary depending on factors such as hydration
status, degree of bladder filling, and patient position.
Finally, uropathies present in a spectrum of severity. As an
example, not all cases of PUV present with a severe UT
dilation. Therefore, minimal UT dilation does not neces-
sarily exclude the diagnosis of PUV. Given the lack of
Table 1 Etiology of urinary tract dilation detected on
antenatal ultrasound.
Etiology Incidence (%)
Transient/physiologic 50e70
Ureteropelvic junction obstruction 10e30
Vesicoureteral reflux 10e40
Ureterovesical junction
obstruction/megaureter
5e15
Multicystic dysplastic kidney disease 2e5
Posterior urethral valves 1e5
Ureterocele, ectopic ureter,
duplex system, urethral atresia,
Prune belly syndrome, polycystic
kidney diseases, l cysts
Uncommon
Adapted from Nguyen et al. 2010 [16].
984 H.T. Nguyen et al.uniformity in the description of the sonographic findings
and paucity of evidence on which to base clinical man-
agement, our goal is to develop a unified classification
system with an accepted standard terminology for the
diagnosis and management of prenatal and postnatal UT
dilation.Methods and conference preparations
Eight societies with a special interest in the diagnosis and
management of fetuses and children with UT dilation (The
American College of Radiology (ACR), the American Insti-
tute of Ultrasound in Medicine (AIUM), the American Soci-
ety of Pediatric Nephrology (ASPN), the Society for Fetal
Urology (SFU), the Society for Maternal-Fetal Medicine
(SMFM), the Society for Pediatric Urology (SPU), the Soci-
ety for Pediatric Radiology (SPR), and the Society of Ra-
diologists in Ultrasounds (SRU)) agreed to collaborate on
the development of a unified grading system for perinatal
UT dilation and propose a standardize scheme for follow-
up evaluation.
The panel consisted of a director (HTN) and 12 panelists
who each have specialized clinical and research experience
with the perinatal diagnosis of UT dilation. The panel
members were appointed by their respective societies and
were representative of several medical disciplines including
obstetrics (maternal fetal medicine, MFM), radiology, pe-
diatric radiology, pediatric urology, and pediatric
nephrology. Prior to the conference, specific aspects of
prenatal and postnatal diagnosis of UT dilation were
assigned to society representatives, based on his/her area
of expertise. The current literature was reviewed and
summarized for presentation (see References).
The consensus conference took place on March 14e15,
2014, in Linthicum, MD. An audience consisting of clinicians
and researchers from the various specialties observed the
proceedings in person or via webinar. The first day of the
conference was devoted to presentations and discussion
regarding the current classification systems for prenatal
and postnatal UT dilation, correlation of prenatal US find-
ings with postnatal outcomes, current recommendations for
postnatal evaluation and follow-up, and long-term renaloutcomes in children with prenatal UT dilation. At the end
of the first day, the panelists spent the evening drafting a
consensus statement. The following day, this statement
was presented to the audience and discussed until the
entire group arrived at a consensus.
Background and summary of the literature
Correlation between prenatal and postnatal US findings
and the ultimate urological diagnosis has been problem-
atic, partly because of the lack of uniformity in defining
and grading urinary tract (UT) dilation. Currently, there
are several grading systems utilized. Some are descriptive
(e.g. mild-moderate-severe [2]); others are quantitative
(e.g. numeric value of the anterior-posterior renal pelvic
diameter (APRPD) [3]) or semi-quantitative (e.g. SFU [4],
European Society of Pediatric Radiology (ESPR), Uroradi-
ology Task Force [5], and Onen grading system [6]). Certain
grading systems are preferentially used in prenatal evalu-
ation while others are preferred for postnatal evaluation.
Based on a survey regarding prenatal diagnosis, MFM phy-
sicians overwhelmingly preferred using the APRPD, while
pediatric urologists were equally divided between using
the APRPD and the SFU grading system [7]. Pediatric radi-
ologists were not included in the survey study results
because most who were surveyed did not perform prenatal
evaluation. For postnatal evaluation, pediatric radiologists
preferred using the descriptive grading system, while
urologists preferred using the quantitative (APRPD) or
semi-quantitative (SFU) grading system [7]. Moreover,
Swenson et al. (publication in progress) demonstrated that
even when the same grading system was utilized, there
was significant inter-rater variability as to which grade a
specific sonographic image represented. All the current
grading systems have less than ideal inter-observer repro-
ducibility (kappa ranging from 0.2 to 0.6 [5,8,9]), and
there are no defined correlations between grading
systems.
A single grading system that can be used across the
prenatal and postnatal time period to describe UT dilation
would be beneficial to promote communication between
different specialists. In the majority of the cases, oral
communication or the report of the findings is not
dependable. Although providing the actual US images
would be optimal, non-imagers may not be familiar with
interpreting gray-scale images, and, in practice, actual
images are often not available. Developing a common
grading system would allow for information transfer
without the ambiguities of interpretation by different
providers. Additionally, by having a consistent grading
system utilized in both the prenatal and postnatal evalu-
ation, more rigorous outcomes research could be per-
formed to correlate the prenatal sonographic findings to
specific consequences such as resolution of renal dilation,
specific uropathies, risks for urinary tract infection, sur-
gery, or renal dysfunction.
Prenatal imaging
In the United States, US evaluation is routinely performed
during pregnancy with an average of two scans for low-risk
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practice guidelines for obstetrical imaging include evalua-
tion of the fetal kidneys and bladder as a required
component of a complete survey [11]. The kidneys and
bladder can be reliably seen on US by the end of the first
trimester [12]. The incidence of detecting UT dilation
prenatally after the first trimester is 1e2%, but is reported
to be as high as 5% in some studies [13]. The majority of
MFM specialists (91%) favor measuring the APRPD to char-
acterize the severity of the renal dilation [7]. Several
studies have evaluated the APRPD of the renal pelvis in
normal fetuses as a function of gestational age to establish
normative data [13,14]. The threshold used for diagnosing
UT dilation based on APRPD typically varies depending on
the gestational age of the fetus. The gestational age ranges
used for various cut-off values were not consistent across
studies, such that the number of gestational age groups and
what cut-off values are applied to each group, is highly
variable and erratic. The most common clinical practice is
to use two gestational age groups, with the first typically
starting in the second trimester (16e20 weeks) and the
second in the third trimester (28e32 weeks). An APRPD of
4 mm is the most common threshold for diagnosing UT
dilation in the earlier gestational age range, and 7 mm in
the older age range [13,14].
Additional US findings that are important for defining the
severity and clinical significance of the prenatal UT dilation
include: laterality, extent of calyceal dilation, paren-
chymal abnormalities, bladder and ureteral abnormalities,
gender, amniotic fluid volume (AFV), and other organ sys-
tem abnormalities. Dilation of the calyces is an important
predictor of clinically significant UT dilation [15]; conse-
quently, some grading systems incorporate the degree of
dilation of the calyces in characterizing the severity of UT
dilation. Grignon et al. [3] proposed five grades of UT
dilation that take into account the measurement of the
APRPD, the degree of calyceal dilation, and parenchymal
thickness. The SFU grading system [4] is composed of five
grades that subjectively evaluate the dilation of the renal
pelvis, distinguish between central (major) and peripheral
(minor) calyceal dilation, and assess parenchymal thickness
with different diagnostic criteria for second trimester and
again for third trimester findings [16]. During the second
trimester, the SFU system defined APRPD as mild for 4 to
<7 mm, moderate 7 to 10 mm, and severe >10 mm.
During the third trimester, mild is defined as APRPD of 7 to
<9 mm, moderate as 9 to 15 mm, and severe as >15 mm.
Correlation with outcomes
Several studies have assessed outcome based on prenatal
APRPD measurements, and most have found that the larger
the APRPD, the more likely it is to be caused by obstructive
uropathies [17e19], the greater the risk of requiring sur-
gery postnatally [18,20e22], and the lower the spontaneous
resolution rate [18,23]. However, it should be noted that
these studies varied widely, applying different APRPD cut-
offs, different gestational age ranges, and different
outcome measures. Looking at the SFU grading system, a
meta-analysis of the literature found that the severity of
UT dilation based on the SFU criteria correlated with uro-
logical pathologies, except for vesicoureteral reflux (VUR)[19,24]. Postnatal pathology (including VUR) was detected
in only 12% of children with isolated second trimester UT
dilation, but in 40% of those with dilation observed in both
the second and third trimester [25]. Progressive UT dilation
observed during pregnancy, rather than lack of progression
or regression, is more often associated with uropathies
[26]. In the diagnosis of lower urinary tract obstruction
(such as from PUVs), oligohydramnios, renal cortical ab-
normalities, and early gestational age at diagnosis (e.g.
<24 weeks) were found to be independent predictors of
poor postnatal renal function [27].
Follow-up fetal imaging
In evaluating the need for follow-up US evaluation, it
has been observed that prenatal UT dilation can resolve
during pregnancy, remain stable, or may progress. The
likelihood of resolution is related to the severity of the
APRPD at initial diagnosis. Prenatal resolution occurred
in approximately 80% of the cases when APRPD was be-
tween 4 and 7e8 mm during the second trimester [28e30],
but less than 15% when APRPD was greater than
9 mm at that stage [28]. Consequently, follow-up US
during the third trimester to assess interval change is
usually recommended. For fetuses in which the UT dila-
tion is mild (4e6 mm prior to 28 weeks gestation and
7e9 mm after 28 weeks onward), follow-up US during the
third trimester detects those in which resolution has
occurred and hence, those that do not require further
prenatal or postnatal evaluation. In cases of moderate UT
dilation (7e10 mm prior to 28 weeks and 10e15 mm
28 weeks onward) and severe cases (>10 mm prior to
28 weeks and >15 mm 28 weeks onward), US is warranted
to evaluate for progression of UT dilation [16,28,30,31].
For the vast majority of cases, follow-up prenatal US
evaluation is sufficient. In a few unique situations, pre-
natal MRI may provide additional information in diagnosis
of UT dilation [32e34].
Fetal pyelectasis on mid-trimester US is associated with
an increased risk of trisomy 21 [35e39]. The sonographic
finding should prompt a targeted anatomic evaluation of
the fetus, and as an isolated finding, carries a likelihood
ratio of 1.5e1.6 for Down syndrome [36]. The finding of
isolated fetal pyelectasis must be interpreted in the
context of the a priori risk of trisomy 21 based on an
accepted screening protocol. In addition, there are mono-
genic syndromes with congenital renal anomalies, some of
which are associated with UT dilation [40].Postnatal imaging
In current clinical practice, it is common that the prenatal
US findings are not available to the physicians taking care of
infants postnatally. Often, it is only mentioned that there is
a history of prenatal kidney problems, without any addi-
tional details characterizing the extent and severity of the
UT dilation. Postnatally, US is often the first imaging mo-
dality to evaluate these patients. In a recent survey of 284
pediatric radiologists with experience in interpreting post-
natal US of UT dilation, 66% utilize the mild-moderate-
severe grading system, while others routinely measure the
APRPD or use the SFU grading system to characterize the
986 H.T. Nguyen et al.severity of the UT dilation (Swenson et al., publication
accepted Pediatric Radiology) Based on intravenous pye-
logram (IVP) [41] and magnetic resonance imaging (MRI)
measurements (Swenson et al., publication accepted Pe-
diatric Radiology), the normal APRPD in children is
commonly considered to be 3 mm at 1 year of age and 6 mm
at 18 years with the 99th percentile for children <5 years of
age being <10 mm. It is important to recognize that these
normative values are based on MRI, while most postnatal
studies are performed with US. Furthermore, the distension
of the urinary tract can be affected by the degree of
bladder distension, hydration, and the position of the pa-
tient in which the US is performed. Furthermore, the ac-
curacy of these measurements may be dependent on the US
image resolution, the site of measurement, the technical
skill of the sonographer, and the supervising physician.
It has been long recognized that the timing of the first
postnatal US is important. Up to 48 h after birth, there is a
tendency to underestimate the severity of hydronephrosis,
in part because of dehydration [41,42]. It is generally rec-
ommended that the first postnatal US be delayed for at
least 48 h after birth, except for cases of oligohydramnios,
urethral obstruction, bilateral high-grade dilation, and
concerns about patient compliance with postnatal evalua-
tion [43]. Hydration can increase the size of a normal renal
pelvis by increasing the volume of excreted fluid and also
by affecting the bladder volume [44e48]. Consequently, it
is recommended that in the presence of UT dilation, the
patient should be rescanned after bladder emptying to
accurately assess the severity of UT dilation. Patient posi-
tion can also affect the accurate measurement of UT dila-
tion, as in many cases the APRPD decreases when measured
in the prone position [49]. As there are pros and cons to
imaging the kidneys in either the prone or supine position,
the current recommendation is that the same position be
used in the same patient during each follow-up measure-
ment to make for more accurate comparisons.
Multiple methods of grading UT dilation postnatally have
been utilized. The descriptive grading system assesses the
degree of renal pelvis dilation, calyceal dilation, and
parenchymal thickness, categorizing variations as mild,
moderate, or severe. This grading system was developed by
correlating US with IVP grading [2]. The SFU grading system
emphasizes the importance of intrarenal calyceal dilatation
rather than the size of renal pelvis [4]. Consequently in this
grading system, the APRPD is not measured. The intra-rater
reliability is good and the inter-rater reliability is modest
using this grading system [8,50]. A meta-analysis of the
literature indicated that the SFU grading system is the most
widely used with the best consistency (11/25 studies) [51].
In an attempt to improve further the accuracy of the
grading system, ESPR proposed a modification of the SFU
grading system in which APRPD was incorporated [5]. Onen
proposed an alternative grading system in which Grade 1
represents pelvic dilation alone, Grade 2 with calyceal
dilation, Grade 3 with less than 50% loss of the renal pa-
renchyma, and Grade 4 with severe loss of renal paren-
chyma [6]. Compared with the SFU grading system, the
Onen system has increased intra-rater reliability but
decreased inter-rater reliability [9].
Alternative US parameters used to evaluate the severity
of the UT dilation include pelvicalyceal area [52],hydronephrosis index (parenchymal to pelvicalyceal area
[53], calyx to parenchymal ratio [54], and pelvicalyceal
volume using 3D US [55]. These methods are more compli-
cated to perform and therefore less commonly used in
routine clinical practice.
In addition to US, IVP and static MR urography (MRU) can
provide additional information on morphology. Diuretic
urosonography, radionuclide renography (NUC), and func-
tional MR urography (MRU) can provide functional infor-
mation. Diuretic urosonography is not widely used. The
assessment of VUR can be performed by radionuclide cys-
tography (RNC), voiding cystourethrography (VCUG), or
contrast enhanced voiding urosonography (VUS).
Correlation with outcomes
Similar to APRPD measured on prenatal US, the APRPD
measured on the first postnatal US correlates with the risk
of uropathies [56]. Multivariate analysis demonstrated that
the severity of renal pelvic dilation, ureteral dilation,
parenchymal thinning, renal hyperechogenicity, and thick-
ened bladder were independently predictive of uropathies.
An APRPD >16 mm (sensitivity Z 99.8%,
specificity Z 89.5%, and OR 106) has been correlated with
the child undergoing pyeloplasty [21]. Recent studies have
attempted to combine several grading systems to improve
correlation with outcomes. Based on multivariate analysis,
Longpre et al. observed that the larger initial APRPD and
SFU Grade 4 both independently predicted lower likelihood
of resolution [57].
Postnatal management
Follow-up US evaluation. An initial normal postnatal US
may be misleading. Aksu et al. observed that 21e28% of
children with prenatal UT dilation had a normal initial
postnatal US [58]; 45% of these children with an initial
normal first postnatal scan had an abnormal US at
follow-up [58]. In another study, 5% of those requiring
surgery for obstructive uropathies had a normal US at 1
week of age but an abnormal US at 1 month of age [26].
It has been reported that approximately 15% of children
with prenatal UT dilation develop later worsening or
recurrent hydronephrosis after an initial normal
postnatal US [59]. Consequently, many advocate that, in
children with prenatal UT dilation, a second postnatal US
should be performed even if the first postnatal US is
normal.
It is generally agreed that those with moderate and se-
vere hydronephrosis (SFU Grade 3 and 4) require earlier and
more frequent postnatal US evaluation than those with mild
(SFU Grade 1 and 2) UT dilation [16]. In a meta-analysis,
SFU Grade 2 resolved in 70% of the cases and SFU Grade 1
and 2 stabilized in 98% of the cases [51]. Sencan et al.
observed in their study population of children with a history
of prenatal UT dilation and mild (SFU Grade 1 and 2)
hydronephrosis on the first postnatal US, that subsequent
follow-up US demonstrated resolution of UT dilation in 67%,
improvement in 13%, stabilization in 16%, and worsening
in 3% [60].
Evaluation for vesicoureteral reflux. In children with a
history of prenatal UT dilation, the incidence of reflux
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observed on the postnatal US, approximately 40% of the
children have VUR, compared with less than 5% when two
postnatal US evaluations are normal [25]. Similarly, in
children with SFU grade 1 and 2 (mild), the incidence of
VUR was 3% [60]. Notably, VUR is the only uropathy in
which the degree of UT dilation observed on the prenatal
and postnatal US does not correlate with increasing risk
of pathology. Moreover, there is poor correlation between
VUR grade and severity of UT dilation [61e64].
Controversies remain over the management of VUR. This
raises the question as to the utility of diagnostic
evaluation for VUR in this population, but this was outside
the scope of this consensus conference.
Functional imaging. It is generally recommended that
children with mild hydronephrosis (SFU Grade 1 and 2) do
not need any functional imaging studies such as nuclear
renography. With moderate (SFU Grade 3), the risk for
surgical intervention was greater in those with differential
renal function (DRF) < 40% (33% vs. 3%) [65]. Most clinicians
recommend that severe hydronephrosis (SFU Grade 4) be
evaluated with functional studies.
Risk for UTI. Systematic review of the literature suggests
benefit of selective use of prophylactic antibiotics in chil-
dren with a prenatal diagnosis of UT dilation [66]. The
incidence of UTI in children with SFU Grade 1e2 was
approximately 5%, compared with 23% in those with SFU
Grade 3e4 [60]. The risk of UTI with and without
antibiotic prophylaxis in children with SFU Grade 1 and 2
or APRPD < 15 mm was similar (2.2% vs. 2.8%), but was
significantly different in those with SFU Grade 3 and 4 or
APRPD 15 mm (14.6% (95% CI: 9.3e22) vs. 28.9% (95% CI:
24.6e33.66), p < 0.01) [66]. The estimated number
needed to treat to prevent one UTI in patients with SFU
Grade 3 and 4 was seven. The risk for UTI is also
significantly higher in those with ureteral dilation [67].
Several studies have suggested that circumcision appears
to be an equally effective alternative to antibiotic
prophylaxis in preventing UTI in children with UT dilation
[66,68,69].
Long-term renal function. Many of the uropathies that
manifest UT dilation prenatally (known collectively as the
Congenital Abnormalities of the Kidney and Urinary Tract or
CAKUT) have concomitant renal developmental anomalies.
In fact, CAKUT is the most frequent cause of chronic kidney
disease (CKD) and end stage renal disease (ESRD) in chil-
dren [70]. How these uropathies affect long-term GFR is
determined by: 1) the extent of renal developmental
injury and its impact on nephrogenesis; 2) the integrity of
the nephron mass that develops and its ability to
maintain renal reserve in the face of normal glomerular
obsolescence and any new insults that may adversely
impact the reserve; and 3) the ability to decrease the
tempo of loss of GFR over time by blunting any
hyperfiltration injury that ensues from reduced renal
reserve.
Nephron development begins early in fetal life and
reaches completion by 35 weeks of gestation. Withmorphologically normal kidneys, there are on average
approximately 600 000e1,000,000 nephrons present at
birth [71]. For most individuals, such a nephron endowment
provides enough renal reserve to maintain renal function
throughout life. Developmental or genetic abnormalities
affecting nephron development or integrity, as well as ac-
quired conditions or renal trauma or surgeries resulting in
nephron loss, can lead to a reduced renal reserve with an
ensuing increased risk of CKD or even ESRD. Children who
are born with a reduced reserve, or who are left with a
significantly reduced reserve early in life, are particularly
at risk for manifesting renal functional abnormalities, as
normal somatic growth places ever-increasing demands on
their already compromised kidneys, in addition to the ef-
fect of hyperfiltration injury.
An individual’s overall GFR reflects the sum of the
filtration that occurs in all of that individual’s functioning
nephrons. As physiologically it is important to maintain
GFR, a compensatory process termed hyperfiltration can
occur when there is a reduced number of functioning
nephrons. In hyperfiltration, the remaining nephrons try to
maintain overall GFR by increasing their single nephron
GFR, essentially increasing their filtration burden to take
over for the absence or loss of normal nephron mass
[72,73]. This process can accelerate normal obsolescence in
these nephrons, leading to glomerular and tubular
dysfunction and in many cases, the ultimate loss of enough
overall function that effective GFR wanes.
As serum creatinine levels are maintained or even
appear better than expected in the early phases of hyper-
filtration, this process may initially present with what looks
like a picture of functional renal adequacy. Over time,
however, with ongoing nephron loss, there can be the
development of proteinuria, hypertension, and renal
insufficiency. In other words, although hyperfiltration may
begin as a compensatory mechanism to maintain function in
a variety of congenital or acquired conditions in which
nephron mass is reduced, the accelerated glomerular
obsolescence that ensues is often a final common pathway
to advanced kidney disease.
In children with CAKUT, high grade obstructing lesions
and diffuse anomalies in development such as hypoplasia
and dysplasia are associated with earlier onset of CKD and
progression to ESRD; however, any prenatally diagnosed
CAKUT increases the risk of CKD substantially. In the gen-
eral pediatric population, CKD is very rare, with a preva-
lence of about 75 cases/million children [74]. On the other
hand, in children with any prenatally diagnosed CAKUT, up
to 6% may manifest CKD by 10 years of age, an 800-fold
increased risk over normal rates [75].
Minimizing new or ongoing insults to the kidney when
there is already pre-existing CKD improves long-term renal
survival and slows down progression to ESRD [76]. Impor-
tantly, recurrent UTI in children is associated with the risk
of new renal scarring and accompanying nephron loss in
children, from 10% with two UTIs to 60% after five UTIs [77].
In addition to addressing any necessary urologic issues such
as obstruction or vesicoureteral reflux, medical manage-
ment of associated sequelae of CKD may have significant
implications for both renal survival and the child’s overall
long-term health. For example, in infants with prenatally
diagnosed CAKUT, the incidence of hypertension increases
988 H.T. Nguyen et al.from <5% in children under 5 years of age to nearly 20% in
older adolescents [75], and uncontrolled hypertension is
certainly a co-factor for accelerating renal dysfunction.
Along these same lines, high-grade proteinuria also por-
tends poorer outcomes such as poorer blood pressure con-
trol [78].
The role of angiotensin blockade in dampening the
progression of chronic kidney disease has been a focus of
attention for many years, especially since the ready avail-
ability of angiotensin converting enzyme inhibitors or
angiotensin receptor blockers. These therapies are well
tolerated, making such intervention attractive to both cli-
nicians and patients [79]. The beneficial role of angiotensin
blockade in CKD is thought to stem not only from anti-
hypertensive effect, but also by general renoprotection as
a result of decreasing intraglomerular filtration pressure,
proteinuria, and profibrogenic cytokines [80].
All of these factors are, in turn, thought to play a role in
the development and progression of hyperfiltration injury
and the loss of renal reserve in CAKUT and other clinical
entities with CKD. There is indeed clinical evidence that in
some populations angiotensin blockade can slow down the
progression from hyperfiltration to albuminuria and can
stabilize proteinuria once present [81].
Accordingly, angiotensin blockade serves at present as
an important adjunctive therapy to blunt disease progres-
sion in children with CKD. As other therapies are developed
to impede disease progression or even to induce disease
regression, accurate risk stratification for children with
abnormal renal development and abnormal urinary tracts
will be of utmost importance to help determine potential
efficacy.
Consensus discussion and statement
The goals of the Consensus Panel
The principal goals for the Consensus Panel were:
1. To propose a unified description of UT dilation that can
be applied both prenatally and postnatally with consis-
tent terminology. This grading system should be simpleTable 2 US parameters included in the Urinary Tract Dilation C
US parameters Measu
Anterior-Posterior Renal
Pelvic Diameter (APRPD)
(mm)
Calyceal dilation Central (major calyces) Yes/N
Peripheral (minor calyces) Yes/N
Parenchymal thickness Norma
Parenchymal appearance Norma
Ureter Norma
Bladder Normabut detailed enough to be meaningful for both clinical
use and future research endeavors. It should also allow
for communication of information between specialists
who care for these patients, both as fetuses and
children.
2. To propose a standardized scheme for the perinatal
evaluation of these patients based on sonographic
criteria; this is intended to be a starting point for
observation and study and will likely require modifica-
tion over time based on the accumulated evidence.
There are several important caveats that the Consensus
Panel considered in developing the following recommen-
dations. First, this grading system is not designed with the
intent of developing a definitive final classification system
for prenatal UT dilation. The proposed grading system is
expected to be validated and/or modified with clinical
experience and evidence-based research results. Second, it
is based on the current available literature, which is
inconsistent and limited. Third, the grading system is
designed to be used in cases of isolated UT dilation and not
to be applied to unique situations or anomalous kidneys
such as solitary, ectopic, multicystic dysplastic kidneys
(MCDK) or other cystic diseases of the kidney. Finally, while
the grading system can be used for post-surgical evaluation,
the proposed scheme for subsequent evaluation is not
intended for application to patients who have undergone
urinary tract surgery.Recommendations
Recommendation #1: terminology
Because of the apparent confusion associated with the
implied meanings of various terminologies for UT dilation,
the Consensus Panel recommended avoiding the use of non-
specific terms in describing UT dilation (e.g. hydro-
nephrosis, pyelectasis, pelviectasis, uronephrosis, UT full-
ness or prominence, and pelvic fullness). The panel
recommends the consistent use of the term “UT dilation.”
Further determination of the severity of UT dilation is
characterized by specific sonographic findings, delineated
by the UTD classification system below.lassification System.
rement/findings Note
Measured on transverse image at the
maximal diameter of intrarenal pelvis
o
o
l/Abnormal Subjective assessment
l/Abnormal Evaluate echogenicity, corticomedullary
differentiation, and for cortical cysts
l/Abnormal Dilation of ureter is considered abnormal;
however, transient visualization of the
ureter is considered normal postnatally
l/Abnormal Evaluate wall thickness, for the presence
of ureterocele, and for a dilated
posterior urethra
Table 3 Normal values for Urinary Tract Dilation Classifi-
cation System.
Ultrasound findings Time at presentation
16e27
weeks
28
weeks
Postnatal
(>48 h)
Anterior-Posterior
Renal Pelvis
Diameter (APRPD)
<4 mm <7 mm <10 mm
Calyceal dilation
Central No No No
Peripheral No No No
Parenchymal
thickness
Normal Normal Normal
Parenchymal
appearance
Normal Normal Normal
Ureter (s) Normal Normal Normal
Bladder Normal Normal Normal
Unexplained
oligohydramnios
No No NA
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information
Communication of prenatal findings to physicians taking
care of the infant postnatally is essential for clinical care as
well as for future outcomes research. The sonographic
findings should be described in accordance with the rec-
ommended grading system, and if feasible, representative
images should be included with the final US report. The
panel recommends that when it is feasible, the parents of
fetuses with prenatal UT dilation and/or the eventual pri-
mary care provider should be provided with the actual US
images. When this is not practical, the panel recommends
providing the family and/or treating physician with the
necessary US findings as delineated by the UTD classifica-
tion system. When the prenatal findings are concerning
enough for a potential need for surgical intervention or risk
for renal compromise, the panel recommends thatFigure 1 Ultrasound appearance of normal fetal kidneys at 32 we
an anterior-posterior renal pelvis diameter (APRPD) measuring < 7
The measurement is taken with the spine at the 12 o’clock position
fluid collection. B: Imaging in the sagittal plan demonstrates norm
This fetus has a normal appearing bladder (not shown) and the ureconsultation prior to delivery with a pediatric urologist
and/or pediatric nephrologist be undertaken to help outline
the care that the child may require postnatally.
Recommendation #3: classification system
The panel concluded that the following sonographic fea-
tures are important factors in characterizing the severity of
the UT dilation (Table 2). The ideal technique for APRPD
measurement is based on images of the kidney obtained
with the fetus or the child in an anterior-posterior plane.
For optimal visualization of the fetal kidneys and mea-
surement of the APRPD, the spine should be demonstrated
at the 12 or 6 o’clock positions. In addition, the measure-
ment should be taken at the maximal diameter of intra-
renal pelvis dilation. In postnatal evaluation, imaging in the
transverse plane at the hilum and in the prone position is
encouraged, although consistency of position (prone or
supine) at the time of measurement should take prece-
dence in serial evaluations.
Additional sonographic features that should be evalu-
ated include: 1) calyceal dilation, making a distinction
between central and peripheral location (recognizing that
this may be difficult to evaluate prenatally, especially
before the third trimester); 2) parenchymal thickness (a
subjective assessment); 3) parenchymal appearance with
respect to echogenicity (subjectively determined by com-
parison with the adjacent liver or spleen), the presence or
absence of cortical cysts and corticomedullary differenti-
ation (the latter finding on postnatal imaging only); 4)
ureteral dilation (transient visualization of the ureter is
considered normal postnatally); 5) bladder abnormalities
such as increased wall thickness, the presence of ureter-
ocele or dilated posterior urethra; and 6) the presence of
otherwise unexplained oligohydramnios on prenatal imag-
ing. We acknowledge that ureteroceles are part of the
ureter and not the bladder, but for simplicity we consider
them as an abnormality in the bladder.
The threshold values for the diagnosis of UT dilation
based on sonographic imaging are stratified based on
gestational age at presentation (Table 3). The renal pelvis is
considered not to be dilated (normal) when the APRPDeks gestation. A: Imaging in the transverse plane demonstrates
mm, which is within the normal range for this gestational age.
and the calipers are placed at the widest part of the intrarenal
al appearing parenchyma and no peripheral calyceal dilation.
ters are not visualized.
Figure 2 Appearance of normal kidneys on postnatal ultrasound. A: Imaging in the transverse plane demonstrates an anterior-
posterior renal pelvis diameter (APRPD) < 10 mm, which is normal for age. Note that the APRPD is measured at the maximal
diameter of intrarenal pelvis dilation rather than that of extrarenal pelvis dilation. B: Imaging in the sagittal plane demonstrates
normal renal parenchyma without any calyceal dilation. The bladder is normal (not shown), and the ureters are not visualized.
990 H.T. Nguyen et al.measures <4 mm at <28 weeks gestation, <7 mm at 28
weeks (Fig. 1A and B), and <10 mm postnatally (Fig. 2A and
B). In the normal fetus, calyceal dilation is absent, the
renal parenchyma has normal thickness and appearance,
the ureter is not seen, and the bladder is normal. Addi-
tionally, there is no unexplained oligohydramnios.Figure 3 Urinary Tract Dilation (UTD) Risk Stratification -
Prenatal Presentation for UTD A1 (low risk) and UTD A2e3
(increased risk). Note: Classification is based on the presence
of the most concerning feature. For example, a fetus with an
anterior-posterior renal pelvis diameter (ARPRD) within the
UTD A1 range but with peripheral calyceal dilation would be
classified as UTD A2e3 (as illustrated in Fig. 5C and D).When the UT dilation is detected prenatally (denoted as
A for antenatally), we suggest stratifying the findings into a
low risk group (UTD A1) and an increased risk group (UTD
A2e3) (Fig. 3). With UTD A1 the APRPD considered to be low
risk for postnatal uropathies is 4 to <7 mm at <28 weeks
(Fig. 4A and B), and 7 to <10 mm at 28 weeks (Fig. 4C and
D). Fetuses in the low-risk category UTD A1 may also have
central calyceal dilation but the presence of peripheral
calyceal dilation is considered to increase risk. The renal
parenchyma has normal thickness and appearance, the
ureter is not seen, and the bladder is normal. There should
not be unexplained oligohydramnios. Fetuses with UTD
A2e3, are considered at increased risk for postnatal urop-
athy, based on an APRPD 7 mm at <28 weeks (Fig. 5A and
B) and 10 mm at 28 weeks, or any one of the following
findings: dilation of peripheral calyces (Fig. 5C and D);
abnormal parenchymal thickness or appearance (Fig. 5E
and F); visibly dilated ureter (Fig. 5G, H, and I); an
abnormal bladder; or the presence of oligohydramnios
suspected to be related to the urinary tract.
Initially, the panel intended to create low (A1), inter-
mediate (A2), and high-risk (A3) groups to parallel the
postnatal classification system, with the distinction be-
tween the intermediate and high-risk groups being dilation
of the central versus the peripheral calyces. However, the
panel noted that based on the literature and clinical
experience, it was often difficult to distinguish between
central and peripheral calyceal dilation on prenatal US.
Consequently, the panel recommends combining the in-
termediate and high-risk groups to create one category of
increased risk (A2e3).
When UT dilation is detected postnatally (denoted as P),
we recommend stratification of risk into three groups: low
risk (UTD P1); intermediate risk (UTD P2); and high-risk
(UTD P3) groups (Fig. 6). With UTD P1, the APRPD consid-
ered to be low risk for postnatal uropathies is 10 to <15 mm
(Fig. 7A and B). Again it should be emphasized that the first
postnatal US should be done more than 48 h after birth to
ensure it does not underestimate dilation, and be repeated
once to ensure the appropriate management. In the low-
risk group, central calyceal dilation may be present, but
again, peripheral calyceal dilation is considered to increase
Figure 4 Ultrasound appearance of UTD A1. A and B: Fetal kidneys at 19 weeks gestation. A: Imaging in the transverse plane
demonstrates an anterior-posterior renal pelvis diameter (APRPD) measuring less than 7 mm, which is within the UTD A1 range for
this gestational age. B: Imaging in the sagittal plane demonstrates normal appearing parenchyma and no peripheral calyceal
dilation. C and D: Fetal kidneys at 37 weeks gestation. C: Imaging the transverse plane demonstrates an APRPD measuring less than
10 mm, which is within the UTD A1 range for this gestational age. D: Imaging in the sagittal demonstrates normal appearing pa-
renchyma and no peripheral calyceal dilation. In each case, the bladder is normal, and the ureters are not visualized (not
illustrated).
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and appearance, the ureter is not seen, and the bladder is
normal. If there is central calyceal dilation but the APRPD is
less than 10 mm, it is still considered UTD P1 (Fig. 7C and
D). With UTD P2, which is considered to be intermediate
risk for postnatal uropathies, the APRPD is 15 mm (Fig. 8A
and B). The calyces may be dilated centrally and periph-
erally or a dilated ureter is visible. For this classification,
the parenchymal thickness and appearance as well as the
bladder are normal. Cases in which there is peripheral
calyceal dilation but the APRPD is less than 15 mm are still
classified as UTD P2 (Fig. 8C and D). Finally, with UTD P3,
the sonographic findings for APRPD, calyceal dilation, and
the ureter are the same as those in UTD P2. However, in
UTD P3, the renal parenchymal is thinned, has increased
echogenicity and/or has decreased corticomedullary dif-
ferentiation, or the bladder is abnormal (wall thickening,
ureterocele, posterior urethral dilation) (Fig. 9A and B).
Cases in which there are parenchymal abnormalities but
the APRPD is <15 mm, are still classified as UTD P3.
Recommendation #4: proposed management scheme
Based on the suggested UTD classification system’s risk
stratification, the panel proposed a follow-up management
scheme. For UTD A1 diagnosed before 32 weeks, a follow-
up prenatal US is recommended at 32 weeks (Fig. 10). If
the US at 32 weeks reveals resolution of the UT dilationwith normal renal parenchyma, bladder and ureters, no
further prenatal or postnatal follow-up is necessary. If
there is persistent UTD A1 or UTD A2e3 (Fig. 3), evaluation
after birth is recommended. Postnatal evaluation should
include two US evaluations: the first at >48 h but less than
1 month after birth; and the second 1e6 months later. In
fetuses considered at increased risk for postnatal uropathy
(UTD A2e3), a follow-up prenatal US is recommended
within 4e6 weeks of the initial diagnosis of UT dilation.
Because of the variability of US findings on prenatal US in
these cases, recommendations for subsequent interval
assessment are at the discretion of the clinician. Prenatal
consultation with a pediatric urologist and/or pediatric
nephrologist is recommended in situations where there is
substantial risk for surgery or renal dysfunction. After birth,
a follow-up US is recommended at >48 h of life but before 1
month. Follow-up should be performed sooner for
obstructive uropathies, such as suspected PUV (as sug-
gested by the finding of a thick-walled bladder with
persistent dilation and a fusiform appearance and/or pos-
terior urethral dilation on prenatal US) or for bilateral
conditions.
For UTD P1, a follow-up US is recommended in 1e6
months (Fig. 11). As there is significant controversy
regarding the clinical importance of diagnosing VUR and the
effectiveness of prophylactic antibiotics, recommendations
for evaluation with VCUG and the use of prophylactic
Figure 5 Ultrasound appearance of UTD A2e3. A and B: Fetal kidneys at 20 weeks gestation. A: Imaging in the transverse plane
demonstrates an anterior-posterior renal pelvis diameter (APRPD) measuring greater than 7 mm, which is within the UTD A2e3
range for this gestational age. B: Imaging in the coronal plane demonstrates normal appearing parenchyma. C and D: Fetal kidneys
at 32 weeks gestation. C: Imaging in the transverse plane demonstrates an APRPD measuring 7 mm, which is below the UTD A2e3
range for gestational age; however, note the presence of peripheral calyceal dilation. D: Imaging in the sagittal plane demonstrates
normal appearing parenchyma but clear peripheral calyceal dilation leading to the classification as UTD A2e3. E and F: Fetal
kidneys at 20 weeks gestation. E: Imaging in the transverse plane demonstrates fluid within the renal pelvis (not measured). F:
Imaging in the sagittal plane demonstrates abnormal appearing parenchyma that is more echogenic than adjacent liver, prompting
classification UTD A2e3. G, H, and I: Fetal kidneys at 32 weeks. G: Imaging in transverse plane demonstrates an APRPD of 8 mm,
which is below the usual range for UTD A2e3 classification. H: Imaging in the sagittal plane demonstrates normal renal parenchyma
and no calyceal dilation. I: However, imaging in the modified sagittal plane demonstrates a clear hypoechoic tubular structure that
has peristalsis in real time, characteristic of a hydroureter. Consequently, the urinary tract classification in this case is UTD A2e3
based on the presence of a visualized ureter on prenatal US imaging.
992 H.T. Nguyen et al.antibiotics are left to the discretion of the clinician. For
UTD P2, a follow-up US is recommended in 1e3 months. As
with UTD 1, recommendations for evaluation with VCUG
and the use of prophylactic antibiotics are left to the
discretion of the clinician. There is significant variability in
the practice of performing functional scans in children with
SFU Grade 3. Consequently, recommendations for func-
tional scans in patients with UTD P2 are left to the discre-
tion of the clinician. For UTD P3, a follow-up US is
recommended within 1 month. Evaluation with VCUG and
the use of prophylactic antibiotics is recommended in this
group, depending in part on the pathology suspected. Aswith UTD P2, recommendation for functional scans in pa-
tients with UTD P3 is left to the discretion of the clinician.
Recommendation #5: modifiers of UTD classification
system
Worsening findings on serial prenatal or postnatal US are
associated with increased risk of genitourinary pathology.
With regards to fetal gender, the panel feels there is
insufficient evidence to suggest that the risk for postnatal
uropathies is significantly different, the exception being
the diagnosis of PUV in males. With regards to unilateral
vs. bilateral UT dilation, there is insufficient evidence to
Figure 6 Urinary Tract Dilation (UTD) Risk Stratification e Postnatal Presentation for UTD P1 (low risk), UTD P2 (intermediate
risk), and UTD P3 (high risk). Note: Stratification is based on the most concerning ultrasound finding. For example, if the anterior-
posterior renal pelvis diameter (APRPD) is in the UTD P1 range, but there is peripheral calyceal dilation, the classification is UTD P2.
Similarly, the presence of parenchymal abnormalities denotes UTD P3 classification, regardless of APRPD measurement.
Figure 7 Appearance of UTD P1 on postnatal ultrasound. A: Imaging in the transverse plane demonstrates an anterior-posterior
renal pelvis diameter (APRPD) 10 to <15 mm. B: Imaging in the sagittal plane demonstrates central but no peripheral calyceal
dilation. The renal parenchyma is otherwise normal. The bladder is normal (not shown), and the ureters are not visualized. Another
example of UTD P1 on postnatal US. C: Imaging in the transverse plane demonstrates an APRPD <10 mm. D: However, imaging in the
sagittal plane demonstrates central calyceal dilation.
Multidisciplinary consensus on the classification of prenatal and postnatal dilation 993
Figure 8 Appearance of UTD P2 on postnatal ultrasound. A: Imaging in the transverse plane demonstrates an anterior-posterior
renal pelvis diameter (APRPD) 15 mm. B: Imaging in the sagittal plane demonstrates peripheral calyceal dilation but normal renal
parenchymal thickness and appearance. In addition, there are no bladder abnormalities (not shown). Another example of UTD P2
on postnatal US. C: Imaging in the transverse plane demonstrates an APRPD <10 mm. D: However, imaging in the sagittal plane
demonstrates peripheral and central calyceal dilation.
994 H.T. Nguyen et al.suggest that the risks for postnatal uropathies are signifi-
cantly different. The panel recommends that stratification
of risk should be based on the grading of UT dilation in the
most severely affected side.
Recommendation #6: reporting
When reporting UT dilation, the panel recommends that a
description of the above seven imaging parameters (Table
3, Figs. 3 and 6) be reported in the written report. In the
Impression section, the specific UTD category (Normal, UTDFigure 9 Appearance of UTD P3 on postnatal ultrasound. A: Imag
renal pelvis diameter (APRPD) 15 mm with peripheral calyceal d
chymal thinning and cysts (arrow). C: Imaging of the bladder demoA1, UTD A2e3, UTD P1, UTD P2, or UTD P3) should be re-
ported along with the suggested management scheme.
Ideally, representative images should be provided with the
report.Discussion
In this consensus statement, the panel integrated existing
grading systems and recommendations and attempted toing in the transverse plane demonstrates an anterior-posterior
ilation. B: Imaging in the sagittal plane demonstrates paren-
nstrates increased wall thickness.
Figure 10 Management schema based on UTD classification
system’s risk stratification of UTD A1 and UTD A2e3.
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system incorporates three broad categories of sonographic
findings e degree of UT dilation, parenchymal quality, and
associated anomalies. Specific aspects of the existing
grading systems have been simplified and incorporated into
a single unified system. Consequently, conversion from
existing grading systems to the UTD classification system
should be relatively uncomplicated. For example, SFU
Grade 1e2 would be equivalent to UTD P1, SFU Grade 3 to
UTD P2, and SFU Grade 4 to UTD P3.
In categorizing the severity of the UT dilation, the panel
felt that it was appropriate to correlate the sonographic
findings to postnatal urological pathology (not transient or
physiologic hydronephrosis) because it was the most
objective and best-characterized outcome identified in the
literature. Further research will be needed to correlate the
UTD classification system risk stratification to other specific
clinical outcomes such as surgical intervention, renal
function, urinary tract infection, and others.Figure 11 Management schema based on Urinary Tract Dilation (
and UTD P3.In addition, the panel recognized that not all urinary
tract dilation is associated with renal pelvic dilation as in
some cases of primary megaureter or reflux where there is
ureteral dilation, but there may be little to no pelvic or
calyceal dilation. The classification system proposed is
primarily for different degrees of renal pelvic dilation and
is thus the main criteria for the UTD classification system
with ureteral dilation as a modifier of renal pelvic dilation.
The visualization of dilated ureter(s) categorizes the UT
dilation as either UTD A2e3 or UTD P2, regardless of the
APRPD measurements.
The panel recommendations are in agreement with the
Executive Summary on Fetal Imaging by NICHD [82]. Spe-
cifically, an abnormal APRPD is defined as  4 mm in the
second trimester and 7 mm at 32 wk. We concur with
the Executive Summary that UT dilation is most often
transient and carries an increased risk of Trisomy 21, war-
ranting a detailed US and correlation with accepted
aneuploidy-screening protocols. In addition, we agree that
follow-up US evaluation should be performed at 32 weeks to
rule out persistent UT dilation. If the APRPD is 7 mm at 32
weeks, we agree with the recommendation of postnatal
radiological evaluation.Future research directions
The Consensus Panel identified several important areas that
require future research evaluation.
1. The proposed grading classification system will require
extensive evaluation to assess its utility in predicting
clinical outcomes. Currently, the grading system is
correlated with the risk of postnatal uropathies. Future
research will help to further refine the classification
system to one that correlates with other clinical out-
comes such as the need for surgical intervention or renal
function.
2. The seven sonographic parameters utilized in the UTD
classification system were selected based on the currentUTD) classification system risk stratification of UTD P1, UTD P2,
996 H.T. Nguyen et al.literature. Further research may help to identify other
US findings that may be more predictive of uropathies
and clinical outcomes.
3. While it is beyond the scope of this consensus statement,
the panel identified that the issue of UTI and the eval-
uation of VUR in children with prenatal UT dilation is
controversial. Prospective studies in this area are
needed to define the role of prophylactic antibiotic or
circumcision and the clinical significance of identifying
VUR in this patient population.Conflict of interest
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postnatal urinary tract dilation (UTD classification system)’
Robin Kremsdorf
The Warren Alpert Medical School of Brown University, Hasbro Children’s Hospital, Department of
Pediatrics, 593 Eddy St., Potter 200, Providence RI 02903, USAAppropriate management of neonatal urinary tract dila-
tion is a challenge to clinicians in variousmedical specialties.
One initial obstacle to good care, or even to high-quality
clinical evidence to guide care, is the lack of a widely
accepted method of categorizing this problem. The devel-
opment of standardized classification criteria for chronic
kidney disease [1] and acute kidney injury [2,3] has allowed
for large-scale studies [4,5] that have greatly advanced our
understanding of these diseases. Currently, many classifica-
tion schemesexist for neonatal urinary tract dilation, noneof
whicharewidely acceptedbyallmedical specialties involved
in the care of patients with this condition.
A new classification and management strategy for
neonatal urinary tract dilation is proposed in this issue of
the Journal of Pediatric Urology. It represents a multidis-
ciplinary consensus among radiologists, urologists,
maternal-fetal medicine practitioners, and nephrologists.
This has great appeal. It allows for all clinicians caring forneonates with urinary tract dilation to have a common
language for communication. Representatives from all
interested parties participated in the development of this
document. There are explicit criteria for classification that
are clear and (for the most part) objective. There are a
small number of categories for classification, which lends
itself to outcomes-oriented research as well as to commu-
nication with patients.
While this consensus statement is useful, it does not
resolve all the obstacles to excellent care of patients
with neonatal urinary tract dilation. It will be meaningful
only if its classification system is widely adopted. As the
authors acknowledge, management recommendations are
vague. This reflects both the lack of conclusive evidence to
guide management and the wide variability in current
clinical practice. As with any guideline, there will be iso-
lated clinical situations where application will not be
appropriate.
